Cargando…

Multicomponent Synthesis of the SARS-CoV-2 Main Protease Inhibitor Nirmatrelvir

[Image: see text] In the wake of the Covid-19 pandemic, it has become clear that global access to efficacious antiviral drugs will be critical to combat future outbreaks of SARS-CoV-2 or related viruses. The orally available SARS-CoV-2 main protease inhibitor nirmatrelvir has proven an effective tre...

Descripción completa

Detalles Bibliográficos
Autores principales:	Preschel, H. Daniel, Otte, Ruben T., Zhuo, Ying, Ruscoe, Rebecca E., Burke, Ashleigh J., Kellerhals, Rachel, Horst, Brendan, Hennig, Sven, Janssen, Elwin, Green, Anthony P., Turner, Nicholas J., Ruijter, Eelco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Chemical Society 2023
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10476182/ https://www.ncbi.nlm.nih.gov/pubmed/37607396 http://dx.doi.org/10.1021/acs.joc.3c01274

Ejemplares similares

A Warhead Substitution Study on the Coronavirus Main Protease Inhibitor Nirmatrelvir
por: Vankadara, Subramanyam, et al.
Publicado: (2022)

Multicomponent Synthesis of 3,6-Dihydro-2H-1,3-thiazine-2-thiones
por: Kruithof, Art, et al.
Publicado: (2012)

Main protease mutants of SARS-CoV-2 variants remain susceptible to nirmatrelvir
por: Ullrich, Sven, et al.
Publicado: (2022)

Stabilization of the Dimeric State of SARS-CoV-2 Main Protease by GC376 and Nirmatrelvir
por: Paciaroni, Alessandro, et al.
Publicado: (2023)

Isocyanide-based multicomponent reactions towards cyclic constrained peptidomimetics
por: Koopmanschap, Gijs, et al.
Publicado: (2014)

Naturally occurring mutations of SARS-CoV-2 main protease confer drug resistance to nirmatrelvir
por: Hu, Yanmei, et al.
Publicado: (2022)

Naturally Occurring Mutations of SARS-CoV-2 Main Protease Confer Drug Resistance to Nirmatrelvir
por: Hu, Yanmei, et al.
Publicado: (2023)

Recent Advances in SARS-CoV-2 Main Protease Inhibitors: From Nirmatrelvir to Future Perspectives
por: Citarella, Andrea, et al.
Publicado: (2023)

Enantioselective Total Synthesis of (−)‐Limaspermidine and (−)‐Kopsinine by a Nitroaryl Transfer Cascade Strategy
por: Horst, Brendan, et al.
Publicado: (2022)

Structural basis of nirmatrelvir and ensitrelvir activity against naturally occurring polymorphisms of the SARS-CoV-2 main protease
por: Noske, Gabriela Dias, et al.
Publicado: (2023)

Alkyne Derivatives of SARS-CoV-2 Main Protease Inhibitors Including Nirmatrelvir Inhibit by Reacting Covalently with the Nucleophilic Cysteine
por: Brewitz, Lennart, et al.
Publicado: (2023)

Autoprocessing and oxyanion loop reorganization upon GC373 and nirmatrelvir binding of monomeric SARS-CoV-2 main protease catalytic domain
por: Nashed, Nashaat T., et al.
Publicado: (2022)

The history, mechanism, and perspectives of nirmatrelvir (PF-07321332): an orally bioavailable main protease inhibitor used in combination with ritonavir to reduce COVID-19-related hospitalizations
por: Joyce, Ryan P., et al.
Publicado: (2022)

Synthesis of Carbazoles by a Diverted Bischler–Napieralski Cascade Reaction
por: Faltracco, Matteo, et al.
Publicado: (2021)

Hotspot residues and resistance mutations in the nirmatrelvir-binding site of SARS-CoV-2 main protease: Design, identification, and correlation with globally circulating viral genomes
por: Padhi, Aditya K., et al.
Publicado: (2022)

H172Y mutation perturbs the S1 pocket and nirmatrelvir binding of SARS-CoV-2 main protease through a nonnative hydrogen bond
por: de Oliveira, Vinicius Martins, et al.
Publicado: (2022)

The Remarkable Selectivity of Nirmatrelvir
por: Duveau, Damien Y., et al.
Publicado: (2022)

Iron‐Catalysed Carbene Transfer to Isocyanides as a Platform for Heterocycle Synthesis
por: Roose, Thomas R., et al.
Publicado: (2022)

Pharmacokinetics of Oral Nirmatrelvir/Ritonavir, a Protease Inhibitor for Treatment of COVID‐19, in Subjects With Renal Impairment
por: Toussi, Sima S., et al.
Publicado: (2022)

Substitutions in SARS-CoV-2 Mpro Selected by Protease Inhibitor Boceprevir Confer Resistance to Nirmatrelvir
por: Gammeltoft, Karen Anbro, et al.
Publicado: (2023)

Nirmatrelvir-ritonavir for COVID-19
por: McDonald, Emily G, et al.
Publicado: (2022)

Nirmatrelvir and ritonavir for COVID-19
Publicado: (2022)

Global prevalence of SARS-CoV-2 3CL protease mutations associated with nirmatrelvir or ensitrelvir resistance
por: Ip, Jonathan Daniel, et al.
Publicado: (2023)

Efficacy comparison of 3CL protease inhibitors ensitrelvir and nirmatrelvir against SARS-CoV-2 in vitro and in vivo
por: Kuroda, Takayuki, et al.
Publicado: (2023)

Nirmatrelvir Plus Ritonavir: First Approval
por: Lamb, Yvette N.
Publicado: (2022)

Nirmatrelvir wirkt auch gegen Omikron
por: Gesierich, Wolfgang
Publicado: (2023)

Possible medication error risks with nirmatrelvir+ritonavir
Publicado: (2022)

Correction to: Nirmatrelvir Plus Ritonavir: First Approval
por: Lamb, Yvette N.
Publicado: (2022)

Nirmatrelvir wirkt auch in der Omikron-Welle
por: Gesierich, Wolfgang
Publicado: (2022)

Nirmatrelvir/Ritonavir for hemodialysis patients with COVID-19
por: Lu, Jiayue, et al.
Publicado: (2023)

The impact of SARS-CoV-2 3CL protease mutations on nirmatrelvir inhibitory efficiency. Computational insights into potential resistance mechanisms
por: Ramos-Guzmán, Carlos A., et al.
Publicado: (2023)

361. Evaluation of Resistance to Nirmatrelvir/ritonavir in Evaluation of Protease Inhibition for COVID-19 (EPIC) High-Risk and Standard-Risk Clinical Trials
por: Lynn Baniecki, Mary, et al.
Publicado: (2023)

Structural dynamics of COVID-19 main protease
por: Shekaari, Ashkan, et al.
Publicado: (2021)

Quaternary Structure of the SARS Coronavirus Main Protease
por: Chang, Gu-Gang
Publicado: (2009)

Possible SARS-coronavirus 2 inhibitor revealed by simulated molecular docking to viral main protease and host toll-like receptor
por: Hu, Xiaopeng, et al.
Publicado: (2020)

Association nirmatrelvir/ritonavir contre la COVID-19
por: McDonald, Emily G., et al.
Publicado: (2022)

Nirmatrelvir–Ritonavir and Viral Load Rebound in Covid-19
por: Anderson, Annaliesa S., et al.
Publicado: (2022)

Nirmatrelvir combined with ritonavir for preventing and treating COVID‐19
por: Reis, Stefanie, et al.
Publicado: (2022)

Benefits of nirmatrelvir–ritonavir remain unproven for some populations
por: McDonald, Emily G., et al.
Publicado: (2022)

Total synthesis of antiviral drug, nirmatrelvir (PF-07321332)
por: Shekhar, Chandra, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_phs05h72pj9crjuvb3209a4mml